ReviewAnesthesiology2020
Genomic Screening for Malignant Hyperthermia Susceptibility.
Review in Anesthesiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 39 citations in OpenAlex.
- To screen or not to screen G6PD deficiency in gNBS: insights from the BabyDetect pilot and current evidence.European journal of human genetics : EJHG · 2026Article
- Clinical and Genetic Spectrum ofMolecular syndromology · 2026Article
- Genetic Testing for Malignant Hyperthermia Susceptibility-Threading the Needle in the Haystack.Genes · 2025Review
- Article
- Biallelic variants in RYR1 and STAC3 are predominant causes of King-Denborough Syndrome in an African cohort.European journal of human genetics : EJHG · 2025Article
- Updating probability of pathogenicity for RYR1 and CACNA1S exon variants in individuals without malignant hyperthermia after exposure to triggering anesthetics.Pharmacogenetics and genomics · 2025Article
- Current Practices in Pharmacogenomics.Pediatric clinics of North America · 2023Review
- A Single-Center Retrospective Review of Patients with Suspected Malignant Hyperthermia Susceptibility.Cureus · 2023Article
- A primordial target: Mitochondria mediate both primary and collateral anesthetic effects of volatile anesthetics.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Updated variant curation expert panel criteria and pathogenicity classifications for 251 variants for RYR1-related malignant hyperthermia susceptibility.Human molecular genetics · 2022Article
- Intravenous dantrolene in hypermetabolic syndromes: a survey of the U.S. Veterans Health Administration database.BMC anesthesiology · 2022Article
- Anaesthetic management of a known or suspected malignant hyperthermia susceptible patient.BJA education · 2021Review
- Sevoflurane may not be a complete sigh of relief in COVID-19.British journal of anaesthesia · 2020Article
- Allele Frequencies and Genotypes for the Ryanodine Receptor 1 Variant Causing Malignant Hyperthermia and Fatal Rhabdomyolysis With Hyperthermia in Horses.Journal of veterinary internal medicineArticle
- Rapid screening for mutations associated with malignant hyperthermia using high-resolution melting curve analysis.Tzu chi medical journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 5 countries.
Funding
Abstract
It is timely to consider the utility and practicability of screening for malignant hyperthermia susceptibility using genomic testing. Here the authors pose a simple, but bold question: what would it take to end deaths from malignant hyperthermia? The authors review recent advances and propose a scientific and clinical pathway toward this audacious goal to provoke discussion in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.